<?xml version="1.0" encoding="UTF-8"?>
<p id="para0025">Clinical trials examining the potential benefit for Bruton's tyrosine kinase (BTK) inhibitors such as ibrutinib (Imbruvica
 <sup>TM</sup>) to protect against lung pathology in patients with COVID-19 are being initiated. The clinical course of six patients who were receiving the drug for Waldenstrom's macroglobulinemia and became ill with COVID-19 was recently reported. The authors proposed that BTK-inhibition may provide protection against lung injury and even improve pulmonary function in hypoxic patients with COVID-19 
 <xref rid="bib0027" ref-type="bibr">[27]</xref>.
</p>
